Novo Holdings

Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.

Hillstar Bio is a biopharmaceutical company focused on developing precision immunotherapies for treating autoimmune diseases. Its innovative approach selectively targets and depletes harmful immune cells, sparing healthy ones, to address specific disease mechanisms and reduce the risks associated with chronic broad immunosuppression. The company aims to provide durable relief and immune reset for patients with autoimmune conditions, addressing unmet medical needs.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Founded in 2021, Commit Biologics is a Danish biotechnology company dedicated to developing innovative immunotherapy platforms for cancer treatment. Its proprietary platform employs b-specific domain antibodies to engage the body's innate immune response, targeting and destroying cancer cells.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

SiteOne Therapeutics is a San Francisco-based company developing innovative therapeutics and diagnostics for acute and chronic pain. Their lead candidates are selective inhibitors of the Naᵥ1.7 ion channel, aiming to treat pain safely and effectively without relying on NSAIDs or opioids.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Kivu Biosciences, based in San Francisco, is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company aims to deliver superior therapeutics and rapidly advance transformative assets, operating discreetly while focusing on its innovative pipeline.

Based on our deep science and focused on patients in need.

Booster Therapeutics is a biotechnology company focused on developing drug modalities to regulate cellular homeostasis and eliminate toxic accumulations. Its primary goal is to reinstate balance within cells, enabling the prevention and treatment of diseases associated with aging.

Convergent Therapeutics is a biotechnology company developing radiopharmaceutical therapies for prostate cancer. Its proprietary platform links monoclonal antibodies targeting prostate-specific membrane antigen (PSMA) with alpha-emitting radionuclides, enabling precise delivery of radiation to cancer cells while minimizing exposure to healthy tissue.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

Draupnir Bio is a biotechnology company focused on developing a new class of cholesterol-lowering medicines to prevent heart blood clots more effectively than existing therapies. The company pursues a platform that maps and leverages the glycome to build heparan sulfate glycomimetics, enabling synthesis, screening, and selection of potent, specific drug candidates for cardiovascular, inflammatory, and infectious diseases. Leveraging its technology, the firm aims to develop protein degraders that target extracellular disease proteins, potentially broadening therapeutic reach across unmet medical needs. The approach seeks to offer convenient treatment options that could reduce reliance on traditional injectables. Through its glycome-based platform, Draupnir Bio targets modalities beyond small molecules, with a focus on extracellular targets and biologics-compatible strategies to improve patient outcomes.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Founded in 2021, Commit Biologics is a Danish biotechnology company dedicated to developing innovative immunotherapy platforms for cancer treatment. Its proprietary platform employs b-specific domain antibodies to engage the body's innate immune response, targeting and destroying cancer cells.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Reunion Neuroscience is a clinical-stage pharmaceutical company focused on developing therapeutic solutions for underserved mental health conditions. Its lead asset, RE104, is a proprietary psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.

Asgard Therapeutics is a private biotechnology company spun out from Lund University that develops in vivo direct cell reprogramming approaches for cancer immunotherapy. It advances a gene therapy platform called TrojanDC that reprograms cells to function as professional antigen-presenting cells, with the goal of initiating and shaping personalized anti-tumor immune responses. The company focuses on generating immune therapies capable of addressing cancers resistant to conventional treatments.

Founded in India over five decades ago, Manipal Hospitals is a prominent healthcare provider with a network of 15 hospitals and three primary clinics. It offers comprehensive curative and preventive care for both domestic and international patients.

Cleveland Diagnostics is a commercial-stage company based in Cleveland, Ohio, focused on developing and commercializing innovative cancer diagnostic tests. Founded in 2013, the company specializes in creating non-invasive screening tools for various cancers, including prostate, breast, ovarian, lung, and certain neurological diseases. Their portfolio includes blood-based tests designed to enhance early detection and improve patient outcomes. Cleveland Diagnostics employs a proprietary solvent interaction analysis technology that examines protein biomarkers at a structural level, offering more precise insights into disease processes and enhancing test specificity. The company has established strategic collaborations with industry partners, such as Genomic Health, to advance its diagnostic capabilities.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Doctor Anywhere is a Singapore-based telehealth company that provides on-demand healthcare solutions. Its digital platform offers quick access to health and wellness services, optimized for convenient lifestyle management.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

MapLight Therapeutics is focused on discovering and developing innovative therapies for brain disorders. The company utilizes a unique platform that integrates single-cell transcriptomics with optogenetics, enabling the identification of novel drug targets. By leveraging these advanced technologies, MapLight aims to create effective treatments tailored to address complex neurological conditions. Founded in 2018 and based in San Francisco, California, the company is committed to advancing the understanding and treatment of brain disorders through its cutting-edge research and development efforts.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Ray Therapeutics develops optogenetic gene therapies to restore vision in patients with blinding retinal diseases. The company designs therapies that use bioengineered light-sensitive proteins delivered to targeted retinal cells via intravitreal injections, with the goal of improving visual function across various forms of retinal blindness and inherited retinal diseases. By combining gene delivery with optogenetic control, Ray Therapeutics aims to provide durable, long-term benefits from a single treatment, addressing diseases that lead to severe retinal degeneration. The company focuses on advancing research and development in this niche field to enable patients with limited or no light perception to regain functional sight, supporting efforts to study rare retinal conditions and translate laboratory insights into potential clinical therapies.

Sangon Biotech Co. is a biotechnology company founded in 2003 as a Sino-foreign joint venture, specializing in the research and development of chemical synthesis of DNA. Over the years, Sangon has established itself as a key player in the global biotechnology market, known for its expertise in DNA synthesis, sequencing, and gene synthesis. The company has invested significantly in its infrastructure, including a manufacturing and industrial base in Songjiang Industrial Park. Sangon offers a wide range of products and services, including molecular biology kits, biochemicals, synthetic genes, oligos, peptide synthesis, enzymes, and laboratory consumables. By providing affordable life science research tools and services, Sangon supports researchers in advancing basic research and product development in the life sciences field.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

LePure Biotech, established in 2011 and headquartered in Shanghai, China, operates within the biotechnology and pharmaceutical sectors. The company specializes in the development and manufacturing of disposable biopharmaceutical process equipment and consumables, primarily focusing on products that facilitate the storage, transportation, filling, and leak detection of samples related to biosimilars, vaccines, and other biopharmaceutical applications. Its core offering is a disposable storage bag designed to meet the specific needs of these processes. Recently, LePure Biotech completed a B+ round of financing, which aims to fund the development of innovative products, establish a research and development center in the United States, enhance supply chain integration, and expand its R&D operations both domestically and internationally.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Doctor Anywhere is a Singapore-based telehealth company that provides on-demand healthcare solutions. Its digital platform offers quick access to health and wellness services, optimized for convenient lifestyle management.

MedGenome develops sequencing-based diagnostics and a research platform that combines genomics technologies, bioinformatics, computing, and big data analytics to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases in diverse populations. The platform enables high-end genetic diagnostic tests across immuno-oncology, infectious diseases, reproductive health, and rare diseases, and serves patients, pharmaceutical companies, and research institutions worldwide by delivering deep insights into diseases at the genetic and molecular level to advance global health.

TheraXyte BioScience is a biotechnology company specializing in extracellular vesicle (EV)-mediated drug delivery and novel EV-based therapeutics. The company has developed an advanced EV-based drug delivery platform called TAXY, which facilitates the mass production of modifiable EVs at a high manufacturing standard. This platform effectively packages payloads and targets specific organs or cells for therapeutic release. TheraXyte's goal is to address various therapeutic challenges by advancing EV research from laboratory settings to clinical applications, ultimately aiming to improve human health through innovative EV-based treatments.

Developer of biotechnology research company designed for the next generation of T cell receptor therapies against cancer. The company engages in the development of TCR-based immunotherapies including T-cell therapies and biologics combining genome editing, functional high-throughput screening, deep sequencing, and machine learning, addressing key efficacy and safety challenges, enabling patients to get the treatment of serious diseases with high unmet medical need.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

Rondo Therapeutics is a biopharmaceutical company based in Hayward, California, specializing in the discovery and development of innovative bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021, the company focuses on creating cancer immunotherapies specifically for solid tumor types that do not respond to existing immune checkpoint inhibitors. By addressing areas of unmet medical need, Rondo Therapeutics aims to advance novel therapeutic options for patients facing challenging cancer diagnoses.

Centauri Therapeutics is a biotechnology company that develops novel immunotherapeutics employing a dual‑mechanism platform. Its molecules combine a cell‑surface antigen‑binding moiety with a glycan effector domain that harnesses the body’s pre‑existing polyclonal antibodies. This design amplifies complement fixation, antibody‑dependent cellular cytotoxicity, and phagocytosis, enabling targeted cell death. The company’s pre‑clinical studies demonstrate potent enhancement of complement fixation and opsonophagocytosis for both antibacterial and oncology agents, and in vivo proof of concept in multiple infection models. Centauri also utilizes alphamer technology, chemically synthesizing molecules that redirect endogenous antibodies to specific pathogens, providing a new approach to treating infectious diseases. The company focuses on life‑threatening conditions, aiming to bring innovative therapies to patients.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Asgard Therapeutics is a private biotechnology company spun out from Lund University that develops in vivo direct cell reprogramming approaches for cancer immunotherapy. It advances a gene therapy platform called TrojanDC that reprograms cells to function as professional antigen-presenting cells, with the goal of initiating and shaping personalized anti-tumor immune responses. The company focuses on generating immune therapies capable of addressing cancers resistant to conventional treatments.

Doctor Anywhere is a Singapore-based telehealth company that provides on-demand healthcare solutions. Its digital platform offers quick access to health and wellness services, optimized for convenient lifestyle management.

Aristea Therapeutics, established in 2018 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious inflammatory diseases. The company focuses on addressing unmet medical needs by creating drugs targeting conditions such as palmoplantar pustulosis, hidradenitis suppurativa, inflammatory bowel disease (IBD), familial Mediterranean fever, and Behçet's disease. Aristea Therapeutics operates with a diligent and agile approach to drug development, aiming to provide patients with access to innovative treatments for these conditions.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Established over two decades ago, BBI Group is a trusted partner to prominent diagnostic and healthcare organizations. Initially founded on the success of its high-quality gold reagents, the company has since expanded into three business units, specializing in diagnostic assay development and manufacturing across various sectors, as well as supplying consumer healthcare products.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. It specializes in developing and manufacturing therapies specifically for rare eye diseases. The company is particularly focused on addressing Stargardt's disease, a juvenile retinal degeneration condition for which there are currently no available treatments. By concentrating on these rare diseases, Stargazer Pharmaceuticals aims to provide healthcare professionals with innovative therapeutic options for patients suffering from such conditions. The company is currently operating in stealth mode as it advances its research and development efforts.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), an essential enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage, working to create a series of first-in-class molecules that aim to reactivate this vital tumor suppressor. With proprietary development tools, Rappta Therapeutics is enhancing its capacity for rational drug design, thus providing therapeutic options for a variety of cancer types and certain important non-oncology conditions.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic respiratory diseases with unmet medical needs. Its lead candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterases 3 and 4 that provides bronchodilation and anti-inflammatory effects in a single molecule. Development programs include formulations of ensifentrine for chronic obstructive pulmonary disease, with options such as nebulized administration, a dry powder inhaler, and a pressurized metered-dose inhaler. Verona Pharma is also pursuing development of ensifentrine for cystic fibrosis and asthma. The company was founded in 2005 and is headquartered in London, United Kingdom.

Reapplix is a Danish medical technology company that develops autologous wound therapy and tissue regeneration solutions derived from the patient's blood. It identifies and isolates blood-derived proteins to accelerate healing of chronic wounds and markets a device capable of delivering autologous active cell therapy to treat diabetic foot ulcers, with the aim of improving healing outcomes and reducing treatment costs. Founded in 2008 and based in Birkerod, Denmark, the company focuses on enabling hospitals to provide biological wound treatment using the patient's own cells.

Bolt Biotherapeutics is a biotechnology company developing cancer immunotherapies based on the Boltbody platform, which links tumor-targeting antibodies to immune-stimulating payloads to activate innate and adaptive immune responses against solid tumors. The platform aims to transform non-responsive, or cold, tumors into immunologically active ones by delivering immune stimulants at the tumor site. The company’s pipeline includes BDC-1001 as a monotherapy for HER2-expressing solid tumors, with additional candidates such as BDC-3042 and Next-Gen ISAC designed to broaden its immuno-oncology program. Bolt Biotherapeutics focuses on myeloid biology and tumor-targeted therapies to leverage immune mechanisms for cancer treatment.

ISD-Immunotech develops a first-in-class therapy targeting the STING pathway to treat severe systemic lupus erythematosus (SLE), also known as lupus. Its therapy dampens the action of stimulator of interferon genes (STING) protein, reducing inflammatory proteins and cytokines that overactivate the immune system in SLE patients.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Hyperbio is developing life-changing therapies by pursuing a novel paradigm in the treatment of Ras-driven cancers.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

WCG is a company focused on accelerating the delivery of new treatments and therapies in the biopharmaceutical sector. It serves biopharmaceutical companies, contract research organizations (CROs), and health institutions by providing a range of services designed to enhance clinical and technological processes. These services include study planning, site optimization, patient engagement, and scientific and market insight solutions. By supporting organizations that develop products and therapies, WCG aims to improve human health and facilitate the efficient advancement of medical innovations.

Draupnir Bio is a biotechnology company focused on developing a new class of cholesterol-lowering medicines to prevent heart blood clots more effectively than existing therapies. The company pursues a platform that maps and leverages the glycome to build heparan sulfate glycomimetics, enabling synthesis, screening, and selection of potent, specific drug candidates for cardiovascular, inflammatory, and infectious diseases. Leveraging its technology, the firm aims to develop protein degraders that target extracellular disease proteins, potentially broadening therapeutic reach across unmet medical needs. The approach seeks to offer convenient treatment options that could reduce reliance on traditional injectables. Through its glycome-based platform, Draupnir Bio targets modalities beyond small molecules, with a focus on extracellular targets and biologics-compatible strategies to improve patient outcomes.

Allievex is a clinical-stage biotechnology company developing novel, non-opioid therapeutics for treating rare pediatric neurodegenerative diseases. Its lead product, tralesinidase alfa, is an investigational enzyme replacement therapy targeting Sanfilippo syndrome type B and mucopolysaccharidosis IIIB in children.

Reapplix is a Danish medical technology company that develops autologous wound therapy and tissue regeneration solutions derived from the patient's blood. It identifies and isolates blood-derived proteins to accelerate healing of chronic wounds and markets a device capable of delivering autologous active cell therapy to treat diabetic foot ulcers, with the aim of improving healing outcomes and reducing treatment costs. Founded in 2008 and based in Birkerod, Denmark, the company focuses on enabling hospitals to provide biological wound treatment using the patient's own cells.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Founded in 2018, Stipe Therapeutics is a Danish biopharmaceutical company dedicated to harnessing the innate immune system for cancer treatment. It focuses on developing first-in-class drugs targeting intracellular protein-protein interactions of the STING pathway, aiming to modulate the tumor microenvironment and enhance anti-tumoral responses.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.